Brainstorm Cell Therapeutics

BrainStorm Cell Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative, autologous cellular therapies for the treatment of neurodegenerative diseases. Their main focus is on their proprietary technology platform, NurOwn®, which involves the use of autologous MSC-NTF cells. These cells are harvested from each individual patient and then manufactured to secrete neurotrophic factors that can potentially help address specific neurodegenerative diseases. Their lead program for NurOwn is for the treatment of Amyotrophic Lateral Sclerosis (ALS), and they have also completed a Phase 2 trial for Progressive Multiple Sclerosis (MS).

The company has received Orphan Drug designation status for NurOwn in both ALS and MS, indicating the potential for NurOwn to address significant unmet needs in these disease areas. BrainStorm has successfully completed a Phase 3 trial in ALS and is now actively working towards initiating a Phase 3b clinical trial to further evaluate the efficacy and safety of NurOwn in patients with ALS. BrainStorm is actively engaged with the ALS community and has a strong commitment to advancing their novel treatment option for ALS patients.

BrainStorm Cell Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative, autologous cellular therapies for the treatment of debilitating neurodegenerative diseases. Their mission is to defeat neurodegenerative diseases by leveraging their best-in-class, autologous cellular therapeutic technology platform, NurOwn®, which has shown promise in treating conditions such as Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS).

BrainStorm Cell Therapeutics promotes a culture of innovation and collaboration focused on delivering life-changing cellular therapies for neurodegenerative diseases. They emphasize a strong scientific foundation, commitment to patient advocacy, and a dedication to achieving regulatory approval for their NurOwn® technology platform.